高价收技术,持续巨亏!探秘天价股权激励背后的故事

星空财研
07 Nov 2024

全文2127字,阅读约需7分钟,帮我划重点划重点01泽辉生物,一家专注于开发多能干细胞(PSC)创新细胞疗法的生物制药公司,于2024年9月30日递表港交所,寻求上市。02然而,泽辉生物面临诸多现实问题,如缺少商业化产品,未来持续性经营能力存疑,核心技术来自授权等。03公司在2022-2024年6月底合计亏损了6.06亿元,累计亏损达到8.11亿元,已陷入资不抵债的情况。04另一方面,泽辉生物对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10